Beyond Weight Loss: New MASH Drug Shows Rapid, Direct Liver Repair

GAITHERSBURG, Md. – July 21, 2026 – In the increasingly competitive race to treat a silent epidemic, a new drug candidate is making noise not just for its efficacy, but for how it works. D&D Pharmatech, a clinical-stage biotech, has published compelling Phase 2 data in The Lancet Gastroenterology & Hepatology for its drug zabopegdutide, demonstrating rapid and significant liver health improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH). The critical finding, however, is that these benefits appear to be largely independent of weight loss, a distinction that could reshape treatment strategies for millions.

MASH, the severe, inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD), affects an estimated 30 million people in major global markets and is on track to become the leading cause for liver transplants. Driven by the global rise in obesity and diabetes, it has spurred a multi-billion dollar race for effective therapies. While recent drug approvals have brought hope, D&D Pharmatech's latest results suggest a new pathway to healing the liver that doesn't rely solely on shedding pounds.

A New Mechanism in a Crowded Field

The newly published 12-week data shows that zabopegdutide (also known as DD01) produced dramatic results in a short timeframe. A remarkable 75.8% of patients treated with the drug achieved at least a 30% reduction in liver fat, with nearly half (48.5%) seeing their liver fat levels return to normal. These improvements were coupled with significant reductions in liver stiffness and key biomarkers of fibrosis, the dangerous scarring that can lead to cirrhosis.

What sets these findings apart is the drug's weight-independent action. Many of the most promising MASH therapies, particularly those in the popular GLP-1 agonist class like semaglutide, are thought to improve liver health primarily as a secondary benefit of the substantial weight loss they induce. Zabopegdutide, in contrast, appears to work directly on the liver.

“Importantly, many of these benefits occurred before meaningful weight loss, suggesting that zabopegdutide provides direct therapeutic effects on the liver beyond weight reduction,” said Seulki Lee, Ph.D., President and CEO of D&D Pharmatech, in a statement. “Together, these findings highlight the differentiated profile of zabopegdutide and support its potential to become a best-in-class therapy for MASH.”

The study data substantiates this claim. Among patients who lost less than 5% of their body weight by week 12—a level not typically considered clinically significant for metabolic disease reversal—zabopegdutide still produced a powerful 37.4% reduction in liver fat. This suggests a potent, liver-focused mechanism is at play from the very beginning of treatment.

The Science of Dual-Agonism

Zabopegdutide’s unique profile stems from its design as a dual-agonist, targeting both the GLP-1 and glucagon receptors. This approach aims to combine the best of both worlds. The GLP-1 component delivers the well-known benefits of improved blood sugar control and reduced appetite, leading to gradual weight loss. The glucagon component, however, adds a powerful and direct liver-centric effect.

Glucagon signaling in the liver boosts energy expenditure and, crucially, enhances the breakdown and mobilization of fat stored in liver cells. By combining these actions, the drug is intended to drive a rapid and robust reduction in liver fat (steatosis) while also delivering systemic metabolic benefits. This dual mechanism provides a compelling scientific rationale for the weight-independent improvements observed in the trial.

“The dual-agonist strategy is one of the most exciting frontiers in metabolic medicine,” noted one industry analyst not affiliated with the study. “While GLP-1s have been revolutionary, their liver benefits can take time and are often proportional to weight loss. A drug that can directly and rapidly de-fat the liver, while also helping with weight and glucose control, could become a foundational therapy for MASH.”

The rapid onset and a short two-week dose titration period also contribute to a favorable profile, potentially improving patient adherence and delivering faster relief from the underlying disease processes.

From Early Markers to Long-Term Hope

The publication provides crucial context for previously announced 48-week data from the same study. In those longer-term results, D&D Pharmatech reported that zabopegdutide achieved statistically significant improvements on the “gold standard” endpoints for MASH trials: MASH resolution and fibrosis improvement, as confirmed by liver biopsy.

The 12-week data now shows that these powerful histological outcomes were predicted by early and substantial changes in non-invasive markers. The ability to see such a strong signal in liver fat, stiffness, and blood biomarkers within three months gives clinicians and patients early confidence that the treatment is working. This correlation validates the use of these less invasive tools to monitor progress and could potentially streamline future clinical trials.

“This publication provides important mechanistic evidence showing that those long-term outcomes were preceded by rapid, objective improvements in non-invasive measures of liver disease,” Dr. Lee added. This rapid feedback loop is a significant step forward for a disease that often progresses silently for years.

Navigating a Multi-Billion Dollar Market

D&D Pharmatech is entering a dynamic and increasingly crowded market, which analysts project could exceed $30 billion within the next decade. The field is no longer a blank slate. Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) and Novo Nordisk’s Wegovy (semaglutide) have already secured FDA approval for MASH, setting a high bar for efficacy and safety.

The pipeline is also packed with formidable competitors, including FGF21 analogues from companies like Akero Therapeutics and 89bio (now part of Roche), and another GLP-1/glucagon dual agonist, survodutide, from Boehringer Ingelheim. In this environment, differentiation is paramount.

Zabopegdutide’s weight-independent mechanism and rapid onset could be its key competitive advantages. This profile may position it as a treatment for a broader range of MASH patients, including those who struggle to lose significant weight or non-obese individuals with MASH. As a smaller biotech, D&D Pharmatech's path forward will likely involve a pivotal Phase 3 trial, followed by a strategic decision on whether to partner with a major pharmaceutical company or become an acquisition target, a common trajectory for successful biotechs in high-value disease areas.

As the company prepares to advance zabopegdutide into late-stage clinical development, the medical and investment communities will be watching closely to see if this rapid, direct-acting approach can secure a leading position in the future of liver disease treatment.